LY3090106 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
53Sjogren syndrome2

53. Sjogren syndrome


Clinical trials : 283 Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04563195
(ClinicalTrials.gov)
December 1, 202112/9/2020BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromeBAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromePrimary Sjogren's SyndromeDrug: tibulizumab (LY3090106)Matthew C. BakerNULLNot yet recruiting18 Years85 YearsAll12Phase 2/Phase 3United States
2NCT02614716
(ClinicalTrials.gov)
December 10, 201524/11/2015A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's SyndromeSjögren's SyndromeDrug: LY3090106;Drug: PlaceboEli Lilly and CompanyNULLCompleted18 Years65 YearsAll32Phase 1United States;Bulgaria;Georgia;Romania